In psoriatic lesions, epidermal keratinocytes overexpress vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) and transforming growth factor alpha (TGF-ll'). TGF-ll' has been shown to induce VEGF/VPF in normal human epidermal keratinocytes i11 vitro. By using a 19-iller antisense phosphorothioate oligodeoxynucleotide (PS-ODN) complementary to bases 6 -24 relative to the translational start site of the VEGF/VPF mRNA, the control sense and mismatched PS-ODNs, we examined modulation of VEGF/VPF induction by Normal human epidermal keratinocytes were treated with PS-ODNs and Lipofectin for 8 h prior to the V ascular e ndothelial g row th f.~cto r /vasc ula r permcability factor (VEGF/VPF) has been shown to playa major role in di scases assoc iated with increased vasc ul ar pe rmea bili ty and an g iogen es is. Overexpression of VEGF/VPF is cvident in many pathologic skin di so rd e rs, in partic ular, p soriasis (Detmar el ai, 1994) , dela yed h yp erse n sitiv ity reactions (Brown et ai, 1995b) , and in some buUous di seases with subepidermal blister formation (Brown el ai, 1995a) .
VEGF/VPF is a homodimeri c 36-46 kDa protein offour isofo rm s ge n erated by alternate spli cin g m cch ani sm s (Ferrara el ai, 1991; T isch er et ai, 1991) . T h c 121-165 amino acid isofonns are secreted, w h ereas the 189-206 am.i no acid isofo rms appe ar to remain cell associated (Park cI ai, 1993 ) . Bal laul1 el al (1995) alld Detmar el al (1995) ha ve shown that the three major spliced forms of V EGFI VPF (189, 165, and 121 amino acids) are produced b y primary cu ltures of hum an ep id e rmal kcratiuocytes. T h e VEGF/VPF secreted by keratinocytes is bi o log icall y active, as it ca uscs a mitogenic response in cultu re d human d e rm al mi crovascular endothelial cell s (Detmal" e/ ai, 1995 addition ofTGF-ll'. Inhibition was assayed at the level of secreted protein by capture ELISA and mRNA expression was assayed by Northern blot analysis. The anti-sense PS-ODN was capable of inhibiting VEGF/VPF RNA and protein to near-basal levels. This inhibition was concentration dependent. No effect was observed with the sense or mismatch control PS-ODNs. These studies suggest that antisense oligonucleotide technology lIlay be a potential therapy for the inhibition of angiogenesis associated with certain skin disorders such as psoriasis. ] I1west Del '-matol 108:523-526, 1997 skin . The two receptors for VEGF/VPF, KDR and At-l (Tcrman el ai, 1992; dc Vries el (/1,1992) , are also overexpressed in und e rlying p apillary d e rm al mi crovascular endoth e lial cell s (Detmar et ai, 1994) . 1n additi o n , lesional psoriatic keratinocytes express e levated levels of transforming growth factor-a (TGF-a) (Elder el ai, 1989 ), a known inducer ofVEGF/ VJ>F expression in primary keratinocyte c ultures (Dctmar et ai, 1994) . A decrease ill TGF-a ha s been observed upon clearance of pso riasis after various treatment regim cns (Watts e/ ai, 1994), and there is evid cnce that VEGF / VPF levels d ecreasc during su ccessful treatment of psoriasis (Detmar and Watts, unpubli sh ed resu lts).
T h e work presented he rein demonstrates d owmegul ation of VEGF/VPF in a TGF-a-indl1cible keratinocyte system u sin g antise nse o li gonucleotide technology. T lus rep ort su ggests the potential clin.i cal application of o li godeoxynl1cleo tides as a topica l treatm ent of skin disorders c haractel'ized by overexprcss io n of VEGFI VPF, enh anced angio gen es is, and /or mi c rovascular permeability.
MATEIUALS AND METHODS
Reagents TGF-O', Trizo l Reagent, and Lipofecti n we re pmchased fro m GIBCO BIU (Gaithersburg. MD). TGF-O' at 100 ng/ml and Lipofectin at 5 J.Lg/ ml were used in all experiments. Affiniry-purified rabbit anti-human VEGF/VPF polyclonal antibody was a gift from Dr. Donald Senger of Beth Israel Hospital, Boston. MA.
Cell Culture Normal hUlllan epidermal kcratinocytes (NHEKs) were purcha sed £i'om C lonetics (Sa n Diego, CAl and grown as rccommended in keratinocyte growth medium. Cell s for all experim ents were used at pass:lge 2 or 3 and cu lturcd in a humidifi ed incuba tor with 1.0% CO~/90% air at 37°C . For antisc nse tteamlCnt. the medium from conAuent cultures was aspirated and replaced with kcratinocyte basal med ium ( 
Human VEGF/VPF Capture ELISA Nun c Maxisorp 96-wcll plates were coated overnight at 4°C with anti-human VEGF/VPF monoclonal antibod), (R & 0 Systems. Minneapolis, MN) and blocked for 2 h with 2% normal human serum. Ce ll supernatants were added and incubated overnight at 4°C. Plates were wash cd three times in 0.05% Tween20/ phosphatebufrcrcd sa lin e on a Dynatech (ChantiUy. V A) plate washer and au affinity-purified n,bbit anti-hun"111 VEGF/VPF po lyclonal antibody (1.5 f.Lg/ml) was added and allowed to incubate for 2 h at 3 rc. Plates were washed as described above and a 1:10,000 dilution of a horse radish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (Kirkegaard and Perry, Ga ith ersburg, MO) was added and allowed to incubate for 1 h at 37°C. ELISA p lates were developcd by using the TMB MicroweU Permcidase Substrate System (Kirkegaard and Perry) and analyzed on a Ceres 900 HDi plate reader (Biotek Instrulllents. Winooski. VT).
Northern Blot Analysis RNA was preparcd using Trizol accord ing to manufa cturer's directions. Total RNA was separated on a 1 % formald ehyde denaturing agarose gel (Ch0111 CZynski and Makey, 1994), transferred to Zeta-Probe (Bio-Rad, Hercules, CAl nylon membrane, as in manuf.,cturer's directions, ,md hybridized to a random-primer-Iabeled simian VEGF/ VPF cONA probc (Shima et aI, :t 996) . A probe for 36B4 . a ribosomc-associated protein (Masiakowski et aI, 1982) . was used to contro l for RNA loading.
The blot was exposed to an imaging screen and sCalmed with a Bio-Rad GS525 Molecular Imager systcm . The acquired image was analyzed by qualltifi~a tion of the signal by volume anal)'sis (miJlim eter~ squared X pixil dcnsity) using the Molecular Analyst softwa re . The numbers shown are the ratios of the VEGF/VPF signal divided by the signa l from the ribosomal protein 3 6B4 .
RESULTS

Uptake of Oligodeoxynucleotides in Normal Human Epidermal Keratinocytes
To determine the uptake of oligodeoxynucleotides, we performed flow cytometry with FITC-ODN. Figure  2a shows a 2.5-fo ld increase in VEGF/VPF expression upon b Data arc normalized to the TGF-Ct'-induccd sa mple without PS-ODN for each time point and expressed as the mean :!: SO (11 = 3).
, Without PS-ODN or TGF-<.Y.
addition of TGF-a. Tllis induction of VEGF/VPF protein was inhibited by treatme nt of the cell s with the antisense PS-ODN prior to TGF-a addition . Inhibition of TGF-a-induced VEGF/VPF expression by the antisense PS-ODN approached 100% willie the sense or mismatch co ntrol PS-ODNs showed little or no effect. T he inhibition ofVEGF/ VPF secretion by the antisense oligonucleotide was concentration dependent (Fig 2b) . Table I summarizes the ELISA resu lts from three expedments . In each experiment, tile antisense PS-ODN (H3) inhibited the induction of VEGF/VPF e":pression mediated by TGF-a to near basa l levels whereas th e control sense PS-ODN (H3S) had little or no eHect.
VEGF/VPF mRNA Levels Decrease After Treatment with Antisense Oligodeoxynucleotides To determine w h ether a decrease in VEGF/VPF protein WaS paralleled by a decrease in VEGF/VPF mRNA, conflue nt keratinocytes were treated with or without PS-ODNs in the presen ce of Lipofectin for 8 h , fo llowed by rep lacement of th e medium with KBM with or without TGF-a. Total RNA was extracted from the ceJJs as describ ed in }\IIaterials alld }\lIe/hods and exa mined by northern blot ana lysis. Figure 3a shows data analysis from a blot hybridized to a VEGF/VPF probe and a 36B4 probe. The results show an increase of VEGF/VPF RNA at 24 and 48 h in cells treated with TGF-a in the presence or ab se nce of sense or mismatched PS-ODNs. Cells treated with the antise nse PS-ODN showed a reduced level ofVEGF/VPF RNA to near-basal levels at both time points exa mined. T his decrease in VEGF/VPF RNA Icvels was paraLleled by a decrease in VEGF/VPF protein accumu lation in th e m edium as assayed by capture ELISA (Fig 3b) while treatment with the control PS-ODN showed little or no e ffect. An uncxp ected d ec rea se at 48 h with the control sense-treated cell s at the RNA le vel was observed. This d ecrease, however, was 110t foHowed by a concomitant decrease in the VEGF/VP F prote in expression . 
DISCUSSION
Al1ti.sen~e therapeutics h ave been suggested for man y clinical a~plicat1ons suc h as v iral infections (human immunodeficiency VITUS, hu.man papilloma virus, he patitis C virus, and human cytomcgalovlrus) and acute mye logenou s le uk emia or m yelodysplastic syndrom e (Fic ld and Goodchild, 1.995). Antiscnse oligonucleotides tar~eted to ml11;ne VEGF/VPF have recend y been shown to inhibit reanal n eovasculari zation in a murine mode l of proliferative retinopath y (Robinson e/ ai, 1996) . In this re~ort , we identify a 19-bp antiscnse PS-ODN (H3) targeted agamst human VEGF/VPF that has th e ability to dOWllregulate TGF-O:'-induced VEGF/VPF expression in human cpidermal keratmocytes. Deli vel), of the PS-ODNs wid, Lipofectin was n ecessat)' to achieve maximal inhibition of the TGF-O:' indu ction of ~GF/VPF. T he use of lipids to efficiently target oligodcoxynucleotldes to th e nucleus and not endosom al vesicles in keratinocytes has bee n d c monstrated previou sly (He rt! e/ ai, 1995) . The TGF-a-induced expression ofVEGF/VPF in normal human epidermal keratinocytes is an attractive model system to examine antisense inhibition of VEGF/VPF because it attempts to simulate the in vi/lo condition where the pathologic progression of psoriasis is associated with an elevati.on of TGF-a levels (Elder et ai, 1989 , Detmar et ai, 1994 Watts ct aI, 1994) . This report sugges ts that antisense oligodeoxynucleotides may have a potential therapeutic role in the treatment of psoriasis.
The possible m echanisms of action of antisense oligodem.:ynucleotides include inhibition of transcription or trans lation and InRNA degradation through an RNase 1-1 cleavage mechanism (Mirabelli and Crooke, 1993) . In our experimental systems, a complctc 2' O-methyl antisense oUgodem. :ynucleotide had Uttlc or no effect on VEGF/VPF expression, while an antisense oligodeoxynucleotide with five 2'O-methyl moieties at the 3' end retained inhibitory activity equal to or slightly better than that of the phosphorothioate molecule (data oot shown). Tlus indicates that RNas e H may play an active role in the observed inlubition ofVEGF/VPF by antisense oligodeoxynucleotides.
VEGF/VPF is a potent inducer of angiogenesis and of microvascu lar p ermeability, and its modulation may play an important ro le in the pathophysiology of several inflammatory and neo plastic skin diseases such as psoriasis (Detmar, 1996) . We have examined the TGF-a-mediated induction of VEGF/VPF in keratinocytes and determined tl1at antisense PS-ODNs are able to inlubit this inducti. on to n ear basal levels. We suggest that by regulating the overexpression ofVEGF/VPF in the skin via 3n antisense oligodeoxynucleotide, it might be . possible to inhibit the VEGF/VPFinduced angiogenic response . A less frequent administration of the therapeutic antisense compound may be feasible because inlubition ofVEGF/VPF was maintained for up to 5 d ill /li/ro. T lus technology may have numerous future appUcatiol1S for skin di sorders characterized by enhanced angiogenesis and/or mi crovascular perm ea bility.
